Company intelligence / Profile preview

Totem Biotech

San Francisco, California, USA

Ownership: Private
Development stage: Other

Overview

Totem is a biotechnology company dedicated to reversing cellular aging and treating age-related diseases through epigenetic reprogramming. The company leverages a proprietary platform to identify and modulate the epigenetic drivers of aging, aiming to restore youthful function to tissues and organs. By targeting the underlying biological mechanisms of aging rather than individual symptoms, Totem seeks to develop transformative therapies for a wide range of chronic conditions. Their approach combines high-throughput screening with advanced computational biology to discover novel epigenetic medicines.

Therapeutic areas: Other
Modalities: Small moleculeEpigenetic modulators
Industry: Biotech

Beyond the preview

Go deeper on Totem Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Totem Biotech.

Explore the full profile